On April 20, Armistice Capital, acting on behalf of the Armistice Capital Master Fund Ltd fund, declared to the AMF that it had fallen below the thresholds of 5% of Nicox capital and voting rights, following the sale of shares on the market.

The declarant stated that it held 2,484,550 Nicox shares representing the same number of voting rights, i.e. 4.95% of the ophthalmology company's capital and voting rights, on behalf of the fund it manages.

Copyright (c) 2023 CercleFinance.com. All rights reserved.